You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Antifungal susceptibility of 149 isolates and categorical agreement between CLSI 2008 and 2012

From: Impact of inappropriate antifungal therapy according to current susceptibility breakpoints on Candida bloodstream infection mortality, a retrospective analysis

Species/ antifungal (n) MIC range (mg/L) MIC 50 (mg/L) MIC 90 (mg/L) CLSI 2008 n (%) CLSI 2012 n (%)
S I R S SDDa/I R
C. albicans (60)
 Fluconazole ≤ 1–8 1 1 60 (100) 56 (93.3) 2 (3.3) 2 (3.3)
 Voriconazole ≤ 0.12 0.12 0.12 60 (100) 60 (100)
 Caspofungin ≤ 0.25–1 0.25 0.25 60 (100) 56 (93.3) 1 (1.6) 3 (5)
 Micafungin ≤ 0.06–1 0.06 0.06 60 (100) 58 (96.6) 1 (1.6) 1 (1.6)
C. tropicalis (34)
 Fluconazole ≤ 1–8 1 1 34 (100) 32 (94.1) 1 (2.9) 1 (2.9)
 Voriconazole ≤ 0.12 0.12 0.12 34 (100) 34 (100)
 Caspofungin ≤ 0.25–1 0.25 0.25 34 (100) 34 (100)
 Micafungin ≤ 0.06–0.5 0.06 0.06 34 (100) 34 (100)
C. glabrata (30)
 Fluconazole ≤ 1–64 4 8 28 (93.3) 2 (6.6) 0 28 (93.3) 2 (6.6)
 Caspofungin < 0.25–1 0.25 0.25 30 (100) 29 (96.6) 1 (3.3)
 Micafungin < 0.06–0.5 0.06 0.06 30 (100) 29 (96.6) 1 (3.3)
C. parapsilosis (15)
 Fluconazole ≤ 1–8 1 8 15 (100) 13 (86.6) 1 (6.6) 1 (6.6)
 Voriconazole ≤ 0.12–0.25 0.12 0.12 15 (100) 15 (100)
 Caspofungin < 0.25–1 1 1 15 (100)    15 (100)
 Micafungin < 0.06–1 0.5 1 15 (100)    15 (100)
C. guilliermondi (3)
 Fluconazole 2–8 2 8 3 (100)   
 Voriconazole < 0.12 < 0.12 < 0.12 3 (100)   
 Caspofungin 0.25–1 0.25 1 3 (100)   
 Micafungin 0.5 0.5 0.5 3 (100)   
C. kruzei (2)
 Voriconazole ≤ 0.12 0.12 0.12 2 (100)    2 (100)
 Caspofungin ≤ 0.25–0.5 0.25 0.5 2 (100)    1 1
 Micafungin 0.12 0.12 0.12 2 (100)    2
Otherb (5)
 Fluconazole ≤ 1–16 2 16 3 (60) 2 (40)  
 Voriconazole ≤ 0.12 0.12 0.12 5 (100)
 Caspofungin ≤ 0.25- > 4 0.25 4 4 (80)
 Micafungin < 0.06- > 4 0.12 4 4 (80)
  1. MIC minimal inhibitory concentration, S susceptible, I intermediate, R resistant, SDD susceptible dose dependent, CLSI Clinical Laboratory Standards Institute
  2. aSDD applies for fluconazole and voriconazole instead of intermediate
  3. bOther species: C. lusitaniae, C. pelliculosa, C. norvegensis, C. lypolitica, C. inconspicua